Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 16, 2014

Advanced Scientifics and Chemic Laboratories Announce Joint Cooperation Agreement

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

Advanced Scientifics (ASI) and Chemic Laboratories reported a three-year joint cooperation agreement that will allow the two companies to collaborate on several product development projects in the pharmaceutical and biopharmaceutical markets, particularly in the areas of leachable and extractable analytical data supporting single-use systems (SUS).

The cooperation model between the two companies will consist of ASI developing film products and SUS systems for pharmaceutical and biopharmaceutical customers, while Chemic uses analytics to provide extractable data assessing material compatibility with model bioprocessing solutions.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.